StevenENissenMD

Preventive Cardiology

Professor of Medicine, Cleveland Cl College of Medicine/Case West Res

Dr. Nissen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
9500 Euclid Ave
Cleveland, OH 44195
Phone+1 800-223-2273

Fax+1 216-445-6855

Dr. Steven Nissen is a cardiologist in Cleveland, OH and is affiliated with Cleveland Clinic. He received his medical degree from University of Michigan Medical School and has been in practice 39 years. He specializes in preventive cardiology and is experienced in general cardiology, lipid disorders, preventive cardiology, hypertension, and coronary artery disease. He has more than 500 publications and over 90,000 citations.

University of Kentucky College of MedicineFellowship, Cardiovascular Disease, 1981 - 1983
University of Michigan Medical SchoolClass of 1978

PubMed

Journal Articles

Coronary Revascularization Strategies
Steven E Nissen, Faisal G Bakaeen, JAMA
Effect of C-reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients with High-Risk Vascular Disease
Steven E Nissen, Jeffrey S Riesmeyer, JAMA Cardiology
Original Investigation Effect of Evolocumab on Coronary Plaque Composition
Steven E Nissen, Ransi Somaratne, Rishi Puri, Christie M Ballantyne, ScienceDirect
Statin Denial: An Internet-Driven Cult with Deadly Consequences
Steven Nissen, MD, Annals of Internal Medicine
Join now to see all

Lectures

ADCY9 Genetic Variants and Cardiovascular Outcomes with Evacetrapib in Patients with High-Risk Vascular Disease
Inova Health System, Mclean, Virginia - 4/26/2013
Debate: The LDL Limbo. How Low Should You Go?
ENDO 2018: 100th Endocrine Society Annual Meeting - Chicago, Illinios - 03/17/2018

Coronary Revascularization StrategiesJuly 2020
Effect of C-reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients with High-Risk Vascular DiseaseJuly 2020
Effect of C-reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients with High-Risk Vascular DiseaseJuly 2020
Effect of C-reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients with High-Risk Vascular DiseaseJuly 2020
ADCY9 Genetic Variants and Cardiovascular Outcomes with Evacetrapib in Patients with High-Risk Vascular DiseaseJuly 2018
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical TrialsMarch 2017
Join now to see all

Lepodisiran Injection Cuts Lipoprotein(A) by 94% in TrialApril 2nd, 2025
Lilly’s Heart Drug Wows as It Reduces Lp(A) by Almost 94% in Phase IIApril 2nd, 2025
Lepodisiran’s Large, Durable Lp(A) Reductions in Phase 2 Trial Boost Anticipation of Phase 3 ResultsApril 1st, 2025
Join now to see all